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Figure 2. Association between anaerobic activity of treatment for peri-
transplant fever during allo BMT hospitalization and subsequent GVHD-
related mortality. Patients treated for peri-transplant fever during allo BMT
hospitalization at MSKCC were treated with antibiotics containing signiﬁcant
activity against obligate anaerobes (piperacillin-tazobactam, ticarcillin-clav-
ulanate, imipenem-cilastatin, meropenem) or with antibiotics without sig-
niﬁcant activity against obligate anaerobes (ceftriaxone, ceftazidime, cefepime,
aztreonam).
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Background: Autologous stem cell transplant (ASCT) is the
standard of care for patients (pts) with relapsed/refractory
Hodgkin lymphoma (HL), providing a cure for approximately
50% of pts; however, most pts with risk factors will progress
post-ASCT (Sureda 2005). Brentuximab vedotin comprises anantieCD30 antibody conjugated by a protease-cleavable
linker to a microtubule-disrupting agent, monomethyl auri-
statin E (MMAE), and has an objective response rate of 75% in
relapsed or refractory HL. The AETHERA trial was initiated to
evaluate whether early treatment with brentuximab vedotin
post-ASCT can prevent progression in pts with HL (Clinical-
Trials.gov #NCT01100502).
Methods: The AETHERA trial is a phase 3, randomized,
double-blind, placebo-controlled, multicenter study. After
ASCT, pts received brentuximab vedotin 1.8 mg/kg q3wk or
placebo for up to 16 cycles. Pts with disease progressionwere
to discontinue therapy and could request unblinding; these
pts may have received subsequent brentuximab vedotin on
another clinical trial or on-label in some regions. The primary
endpoint is progression-free survival (PFS) per an indepen-
dent review facility (IRF).
Results: A total of 329 pts were randomized at 78 sites in the
US and Europe. The median age was 32 years (range, 18e76)
and 53% were male. Pts were enrolled in 1 of 3 high-risk
categories: refractory to frontline (FL) therapy: 196 pts (60%),
relapse <12 mos after FL therapy: 107 pts (33%), and relapse
12 mos after FL therapy with extranodal disease: 26 pts
(8%). Response to salvage therapy pre-ASCT was complete
remission: 137 pts (42%), partial remission: 112 pts (34%),
and stable disease: 80 pts (24%). The median number of prior
systemic therapies was 2 (range, 2e8); 47% of pts received
more than 2 prior systemic therapies. Prior to pre-ASCT
salvage therapy, 106 pts (32%) had extranodal involvement
and 87 pts (26%) had B symptoms. Prior to ASCT,110 pts (33%)
were PETenegative, 116 pts (35%) were PET-positive, and PET
status was unknown for 103 pts (31%). All pts had completed
or discontinued study treatment as of August 2013. The
median number of treatment cycles was 15.
Adverse events (AEs) of any grade in >15% of all pts were
peripheral sensory neuropathy (36%), upper respiratory tract
infection (25%), neutropenia (24%), fatigue (21%), cough
(19%), and pyrexia (17%). Grade 3 or higher AEs in 10 pts
were neutropenia (20%), peripheral sensory neuropathy (6%),
thrombocytopenia (3%), and peripheral motor neuropathy
(3%).
The primary results were released on September 29th,
2014. The PFS per IRF for patients who received brentuximab
vedotin was statistically signiﬁcantly improved compared to
patients who received placebo (hazard ratio 0.57; P¼0.001).
Conclusions: Brentuximab vedotin signiﬁcantly improved
the post-ASCT PFS of patients with HL. Complete efﬁcacy and
safety data will be presented at the conference.5
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Background: Hematopoietic stem cell (HSC) gene therapy
has the potential to induce globin production in the RBC
Table I
Dosing parameters and gene-therapy outcomes1
Subject Age (years)
gender
Genotype LentiGlobin transduced CD34+
cells
Day of ANC
engraftment
bAT87Q-Hb/Total
Hb (g/dL)
(day of test)
Last PRBC
transfusion
VCN Dose (x106 per kg)
205-1201 19, F b0/bE 1.5 8.9 day +13 7.2/10.2 (day+180 ) Day+10
205-1202 16, M b0/bE 2.1 13.6 day +15 6.8/11.0 (day+135) Day+15
204-1102 18, F b0/bE 1.0/1.12 6.5 day +17 1.7/8.6 (day + 90) Day+14 and+96
1Data as of 31 July 2014; 2more than one drug product were manufactured.
Data being presented on behalf of all HGB-204 and 205 Study Investigators.
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tients with b-thalassemia major. Transplantation with
autologous CD34+ cells transduced with a replication-
defective, self-inactivating lentiviral vector (LentiGlobin
BB305) containing an engineered b-globin gene (bAT87Q)
resulted in early reduction or elimination of transfusion re-
quirements in the ﬁrst 3 subjects treated in the ongoing
HGB-204 and 205 studies. Herein, we provide additional
follow-up data on the three subjects.
Subjects and Methods: Transfusion-dependent subjects
with b-thalassemia major undergo HSC collection via mobi-
lized peripheral blood apheresis and CD34+ cells are selected.
Estimation of the mean ex-vivo vector copy number (VCN) is
obtained by quantitative PCR performed on pooled colony-
forming progenitors. Subjects undergo myeloablation
with intravenous busulfan (Bu), followed by infusion of
transduced CD34+ cells. Subjects are monitored for hema-
tologic engraftment, bAT87Q-globin expression (by high
performance liquid chromatography) and transfusion re-
quirements. Integration site analysis (ISA, by linear ampliﬁ-
cation-mediated PCR and high-throughput sequencing on
nucleated cells) and replication-competent lentivirus (RCL)
assays are performed for safety monitoring.
Results: 3 subjects (b0/bE) have undergone gene therapy via
infusion of transduced CD34+ cells. Outcomes data are
shown in Table I. All adverse events to date were related to
Bu conditioning, without any serious or gene therapy-
related adverse events. All three subjects are producing
bAT87Q-globin and the ﬁrst two subjects remain transfusion
independent after a median follow-up of 150 days (range:
127-246 days). Details of patient eligibility, vector design,
interpretation of post-transplant VCN, and details of safety
monitoring (ISA and RCL analysis) for gene therapy of
thalassemia will be discussed. Major differences between
BMT and gene therapy for thalassemia will be highlighted.
Conclusion: Ex-vivo gene transfer of bAT87Q-globin to autol-
ogous HSCs has resulted in clinically beneﬁcial production of
b-globin and may be a promising approach for the treatment
of patients with b-thalassemia major.6
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Promising results have been reported for patients with
high-risk hematologic malignancies undergoing T-cell-
replete myeloablative hematopoietic stem cell trans-
plantation (HSCT) from HLA-haploidentical donors with
post-transplantation cyclophosphamide (PT/Cy). Here, we
report the largest patient experience (n¼97) for leukemias in
complete remission (CR) and chemosensitive lymphomas
with at least a partial remission (PR) enrolled on, or treated
according to, our now completed single-institution phase II
clinical trial. Conditioning consisted of IV Busulfan (phar-
macokinetically adjusted) days e6 to e3 and Cy (50 mg/kg/
day) days e2 and e1 except for patients with acute lym-
phocytic leukemia or lymphoblastic lymphoma who
received Cy (50 mg/kg/day) days e5 and e4 and total body
irradiation (200 cGy twice daily) days e3 to -1. T-cell-replete
bone marrow from haploidentical related donors was used
for all patients. Postgrafting immunosuppression consisted
of Cy (50 mg/kg/day) days 3 and 4, followed by mycophe-
nolate mofetil for 30 days and tacrolimus for 6 months.
Ninety-seven patients with a median age of 42y (range, 1-65)
were treated. Diagnoses included AML (CR1¼24, CR>2¼10,
any CR with minimal residual disease¼11), ALL (CR1¼9,
CR>2¼4, any CR with minimal residual disease¼6), mixed
lineage leukemia (2), MDS (13), CML (chronic phase 2¼2),
CMML (1), CLL (1), granulocytic sarcoma (2), multiple
myeloma (1), lymphoma in chemosensitive PR (5), and
lymphoma in CR (6). Donor engraftment occurred in 73/82
(89%) patients evaluable at Day 60. Median time to neutro-
phils >500/mL was 23 days and platelets >20,000/mL was 27
days. Cumulative incidences of acute GVHD grades II-IV and
grades III-IV at day 100 were 17% and 7%, respectively, and
chronic GVHD at 6 months was 16%. Transplant-related
mortality (TRM) at 100 days was 11%. The cumulative inci-
dence of relapse at 3y was 44%. For leukemia patients in CR
with no detectable MRD the cumulative incidence of relapse
at 2y was 33% in CR1 and 27% in >CR2. For leukemia patients
in any CR with detectable MRD by ﬂow cytometry and/or
cytogenetics and/or FISH, the cumulative incidence of
relapse at 2 years is 70%. Among lymphoma patients, the
cumulative incidence of relapse at 2y for those in CR is 33%
and in PR 25%.With a median follow-up of surviving patients
of 474 days (range, 60-1782), actuarial overall survival is 72%
at 1y and 57% at 2y. With a median follow-up of event-free
patients of 444 days (60-1782), actuarial event-free survival
is 55% at 1y and 49% at 2y. For the largest reported patient
population undergoing myeloablative HLA-haploidentical
HSCT for high-risk hematologic malignancies with T-cell
replete bone marrow and PT/Cy, we have demonstrated
acceptable rates of engraftment, GVHD, relapse, survival, and
TRM, similar to HLA-matched HSCT. This approach is there-
fore a feasible option for high risk patients who lack timely
access to an HLA-matched donor.
